US Cases / Year
~154,000
Third most common cancer in the US. Approximately 154,000 new cases annually (ACS 2024).[1]
What Is It
Definition, mechanism, and the clinical reality of colorectal cancer at end of life. What the hospice team needs to understand on day one.
Stage IV at Presentation
~20%
One in five patients present with distant metastatic disease at initial diagnosis.[2]
5-Year Survival, Stage IV
~15%
Stage IV 5-year relative survival approximately 15%. With peritoneal mets, significantly worse.[2]
Peritoneal Mets Prevalence
~25%
Approximately 25% of metastatic CRC patients develop peritoneal carcinomatosis — a harbinger of obstruction and rapid decline.[3]
Colorectal cancer (CRC) is a malignant tumor arising from the epithelial lining of the colon or rectum. It encompasses cancers of the colon (ICD-10 C18.x), rectosigmoid junction (C19), and rectum (C20). Over 95% are adenocarcinomas. The colon is divided into right-sided (cecum, ascending, transverse) and left-sided (descending, sigmoid, rectum) segments — a distinction with meaningful clinical and molecular implications at the hospice bedside. Right-sided tumors tend to grow as large fungating masses causing anemia; left-sided tumors narrow the lumen concentrically, creating obstruction, rectal bleeding, and tenesmus.[1]
In the palliative and hospice setting, CRC presents a constellation of challenges unlike most solid tumors: the gut itself becomes the battlefield. Bowel obstruction, bleeding from tumor erosion, fistula formation, fecal diversion via ostomy, and unrelenting pelvic pain define this disease's final chapters. Approximately 15% of non-metastatic CRC is microsatellite unstable (MSI-H/dMMR) — this subtype has markedly different prognosis, responds to immunotherapy, and is found in Lynch syndrome families. MSI-H status remains clinically relevant even at hospice enrollment.[4]
🧭 Clinical framing
The defining end-stage complication of colorectal cancer is malignant bowel obstruction — and it is not a surgical emergency in a comfort-focused patient. It is a medical management problem. Lead with that reframe. When the ER calls about your CRC patient with an obstruction on CT, the answer is not surgery. The answer is octreotide, dexamethasone, haloperidol, and a conversation. Surgery for bowel obstruction in stage IV CRC with peritoneal carcinomatosis carries 40–90 day perioperative mortality of 20–40% and does not improve long-term outcomes. Every clinician on this team must internalize this before they walk into the patient's home.[5]
"Every CRC patient you admit to hospice is going to have the bowel obstruction conversation — either before it happens or during the crisis. Do it before. Tell them: 'If your bowel blocks, we have medications that work. Surgery at this point is more likely to kill you than help you. We will keep you comfortable at home.' Say it plainly. Say it early. Say it every visit until they believe you."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, biomarkers, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Colonoscopy with biopsy: Gold standard for diagnosis. Histopathology confirms adenocarcinoma type and grade.
- CT chest/abdomen/pelvis: Staging and metastatic evaluation. CT colonography if scope not possible.
- PET/CT: For equivocal lesions or restaging after treatment.
- CEA (Carcinoembryonic antigen): Tumor marker used for monitoring response and recurrence — not diagnostic. Rising CEA in hospice patient signals disease progression.[6]
- MSI/MMR testing: Critical — determines immunotherapy eligibility (pembrolizumab) and prognosis. MSI-H tumors have better prognosis and respond to checkpoint inhibitors. Also identifies Lynch syndrome families.[4]
- RAS/BRAF mutation status: KRAS/NRAS mutations preclude anti-EGFR therapy (cetuximab, panitumumab). BRAF V600E mutation confers poor prognosis.
What to Look for in Hospice Records
- Ostomy presence and type: Colostomy vs ileostomy vs urostomy — each has different management, output expectations, and complication profiles. Know which your patient has.[7]
- Peritoneal carcinomatosis on prior imaging: If present, changes the prognostic clock dramatically — median survival 6–12 months from diagnosis of peritoneal mets.
- Liver metastasis burden: Isolated liver mets behave differently from diffuse hepatic disease. Elevated bilirubin and albumin <2.5 signal hepatic failure.
- Prior bowel resections: What anatomy remains? Hemicolectomy, LAR, APR — each changes obstruction anatomy and presentation.
- MSI-H status: Relevant for family counseling about Lynch syndrome even at hospice enrollment — first-degree relatives face 50% inheritance risk.[4]
- Performance status trend: ECOG trajectory over last 3 months — rapid decline vs slow glide matters for prognosis.
💡 For families
💡 Para las familias
Most of the diagnostic workup is already complete when your loved one enters hospice. The tests have been done; the results are known. The focus now shifts entirely to comfort. If you hear unfamiliar terms in medical records — CEA, MSI, BRAF — ask the hospice nurse to explain what they mean for your loved one's care going forward.
Próximamente en español. — Coming soon in Spanish.
Causes & Risk Factors
Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Modifiable Risk Factors
- Red and processed meat consumption: Well-established risk factor. WHO classifies processed meat as Group 1 carcinogen for CRC.
- Obesity and physical inactivity: BMI >30 increases CRC risk 1.3–1.5x. Physical activity reduces risk by 20–25%.
- Heavy alcohol use: ≥3 drinks/day associated with increased risk.
- Tobacco smoking: Long-term smoking increases CRC incidence and mortality.
- Inflammatory bowel disease: Crohn's disease and ulcerative colitis — risk increases with duration and extent of colitis.
- Type 2 diabetes mellitus: Independent risk factor, likely related to insulin resistance pathways.
Hereditary & Non-Modifiable
- Age >50: Risk doubles each decade after age 50. However, CRC incidence is rising in people under 50 — screening age now lowered to 45.[8]
- Lynch syndrome (HNPCC): MLH1, MSH2, MSH6, PMS2 mutations. 3–5% of all CRC. Autosomal dominant. Lifetime CRC risk 40–80%.
- Familial adenomatous polyposis (FAP): APC gene mutation. Near 100% CRC risk without prophylactic colectomy.
- Personal/family history of polyps or CRC: First-degree relative with CRC doubles risk.
- MUTYH-associated polyposis: Autosomal recessive. Moderate increase in CRC risk.
⚠ Health Disparity Note
Black Americans have higher incidence and mortality from CRC than white Americans and present at younger ages. Screening disparities are well documented — Black patients are less likely to receive timely screening, more likely to be diagnosed at advanced stages, and receive less equitable end-of-life care. Be especially attentive to systemic barriers, patient distrust, and communication gaps in these interactions. This is not the patient's problem to solve — it is ours.[9]
❤️ For families: "Why did this happen?"
Families always ask this. Most colorectal cancers develop from a combination of age, genetics, and environmental factors over many years. This was not caused by something your loved one did wrong. For families where Lynch syndrome is confirmed or suspected, first-degree relatives face significant cancer risk — genetic counseling is appropriate and can save lives in the next generation. Don't skip this conversation because the patient is dying.
⚕ Clinician note: Genetic counseling at hospice enrollment
Even at hospice enrollment, referral for genetic counseling is appropriate when Lynch syndrome is identified or suspected. This can identify at-risk family members who benefit from enhanced surveillance. The patient may not benefit, but their children and siblings can. Document the conversation and provide contact information for genetic counseling services.
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret trajectory.
Know what surgery has already altered the GI anatomy — it changes obstruction presentation and management. A patient who had a right hemicolectomy has different obstruction anatomy than one with an APR. A patient with a diverting loop ileostomy still has downstream colon that can obstruct. Read the operative reports. Know what's been done and what remains.
Surgical Procedures
Curative / Prior Surgery
- Right hemicolectomy: Removes cecum, ascending colon, hepatic flexure. Ileocolic anastomosis.
- Left hemicolectomy / Sigmoidectomy: Removes descending colon and/or sigmoid.
- Low anterior resection (LAR): For mid-rectal tumors. Preserves sphincter. May have temporary loop ileostomy.
- Abdominoperineal resection (APR): For low rectal cancer. Creates permanent colostomy. No rectum remains.
- Hartmann's procedure: Emergency obstruction surgery. End colostomy with closed rectal stump.
Palliative Procedures
- Colonic stent (SEMS): For malignant large bowel obstruction. Hospice-compatible. Achieves >97% symptom resolution. Avoid in patients on bevacizumab (perforation risk).[10]
- Diverting colostomy: Rarely appropriate in hospice but discuss for select patients with obstruction below the stoma site.
- Venting gastrostomy (PEG): For intractable obstruction nausea/vomiting. Decompresses stomach, restores comfort oral intake, reduces hospital readmissions.[11]
- Paracentesis: For malignant ascites from peritoneal carcinomatosis. Frequency >every 2 weeks is a poor prognostic marker.
Chemotherapy Regimens
| Regimen | Components | Line | Notes for Hospice |
|---|---|---|---|
| FOLFOX | 5-FU + Leucovorin + Oxaliplatin | 1st / 2nd | Peripheral neuropathy persists into hospice. Affects hand/foot function. |
| FOLFIRI | 5-FU + Leucovorin + Irinotecan | 1st / 2nd | Diarrhea may persist. UGT1A1 poor metabolizers at higher toxicity risk. |
| FOLFOXIRI | 5-FU + LV + Oxaliplatin + Irinotecan | 1st (aggressive) | ±Bevacizumab. PFS 12.1 vs 9.7 mo (TRIBE trial).[12] |
| CAPOX/CAPEOX | Capecitabine + Oxaliplatin | 1st / 2nd | Oral 5-FU prodrug. Hand-foot syndrome. |
| TAS-102 (Lonsurf) | Trifluridine + Tipiracil | 3rd+ | Oral. Myelosuppression. Modest OS benefit in refractory disease. |
Targeted & Immunotherapy
Anti-VEGF
Bevacizumab — added to doublet/triplet chemo for all RAS subtypes. Risk of bowel perforation, bleeding, and fistula — directly relevant if your hospice patient has a stent or prior abdominal surgery.
Anti-EGFR (RAS Wild-Type Only)
Cetuximab, Panitumumab — for left-sided KRAS/NRAS/BRAF wild-type. Acneiform rash and hypomagnesemia may persist into hospice. Diarrhea common.
Immunotherapy (MSI-H Only)
Pembrolizumab — for MSI-H/dMMR tumors. Can produce durable responses even in heavily pretreated patients. Immune-related adverse events (colitis, hepatitis, pneumonitis) may require steroids in hospice.[4]
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
First-line CRC survival data supports concurrent palliative care integration from diagnosis. NCCN guidelines recommend early palliative care involvement for all patients with metastatic CRC. The question is never "palliative care or treatment" — it is "when does treatment stop serving the patient's goals?"[13]
- 01Performance status ECOG 0–2: Patients with preserved functional status tolerate and benefit from systemic therapy. At ECOG ≥3, chemotherapy shows no survival benefit and increases toxicity and hospitalization.[14]
- 02MSI-H tumor with pembrolizumab response: MSI-H/dMMR patients may achieve durable responses to immunotherapy even in later lines. If MSI-H status was identified but immunotherapy never tried, this conversation is clinically appropriate — even near hospice enrollment.[4]
- 03RAS wild-type with EGFR antibody response: Left-sided KRAS/NRAS/BRAF wild-type tumors respond to cetuximab or panitumumab with meaningful survival extension when added to chemotherapy backbone.
- 04Liver-limited disease with resection potential: Occasionally, patients with oligometastatic liver-only disease may still benefit from resection — 5-year survival ~40–60% post-hepatectomy in selected patients. This is a narrow window but real.[15]
- 05Patient goals explicitly include life-prolongation: A well-informed patient who fully understands prognosis and chooses active treatment should receive it without judgment. The key word is "well-informed."
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Palliative chemotherapy use close to death is associated with less hospice utilization, more ER visits, and more ICU admissions. Patients who inaccurately believed their chemotherapy could cure them were significantly less likely to enroll in hospice (OR 0.25). When the clinical picture points to progression despite all treatment, the goal-directed conversation must happen before the next infusion is ordered.[16]
- 01Progression through ≥2 lines of chemotherapy: After FOLFOX + FOLFIRI (or equivalent), salvage therapy offers diminishing returns. Third-line agents (TAS-102, regorafenib) provide modest survival benefit (weeks, not months) with significant toxicity.
- 02ECOG ≥3: No survival benefit from chemotherapy. Increased toxicity, hospitalization, and treatment-related death. This is the clearest stop signal in oncology.[14]
- 03Peritoneal carcinomatosis with recurrent obstruction: Multifocal peritoneal disease causing repeated bowel obstruction is not amenable to surgical cure. Median survival after MBO in stage IV CRC: weeks to a few months.[5]
- 04Malignant ascites requiring frequent paracentesis: Taps needed more frequently than every 2 weeks signal rapidly progressive peritoneal disease and are a poor prognostic marker.
- 05Severe protein-losing enteropathy: Albumin <2.5, peripheral edema, inability to maintain nutritional status — the body cannot sustain systemic therapy.
- 06Estimated survival <6 months: Hospice enrollment is appropriate, beneficial, and guideline-supported. All thresholds above converge here.
📋 The surgical conversation — say it directly
At end-stage CRC with peritoneal disease, surgical intervention for bowel obstruction carries 40–90 day mortality of 20–40% and does not improve long-term outcomes. The ER will want to scan it. The surgeon will want to cut it. Your job is to be the voice of the patient's goals. Medical management with octreotide, dexamethasone, haloperidol, and a venting gastrostomy is the right answer in a comfort-focused patient. Document the conversation. Document the evidence. Protect your patient from surgery that will end their life in the hospital instead of at home.[5]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = strong RCT evidence; B = multiple observational/meta-analyses; C = limited clinical, signal present; D = expert opinion.
Ginger for Nausea
Grade A250–500 mg ginger extract TID-QID or 1–2 g powdered ginger daily
Strong evidence for chemotherapy-induced and general cancer-related nausea. Safe and well-tolerated in hospice populations. Ginger tea (1–2 g fresh grated in hot water) is an accessible option. Avoid in complete bowel obstruction (oral route contraindicated). Monitor for additive antiplatelet effect with anticoagulants.[17]
Acupuncture for Pain & Nausea
Grade B2–3 sessions/week; adaptable to bedside in hospice
Grade B evidence specifically in GI cancer populations for pain and nausea control. Acupuncture at PC6 (Neiguan) for chemotherapy-induced and cancer-related nausea has been studied in multiple RCTs. Safe adjunct when available. May reduce opioid requirements in some patients.
Probiotics for Chemo-Related Diarrhea
Grade BLactobacillus/Bifidobacterium strains; strain-specific dosing varies
Multiple RCTs show reduction in chemotherapy-related diarrhea with probiotics. Grade B evidence. Caution in immunosuppressed patients — risk of bacteremia with live cultures in neutropenic or severely debilitated patients. Not appropriate for complete bowel obstruction.
Mindfulness / MBSR
Grade B8-week MBSR program adapted; guided meditation 15–30 min/day
ACCP-level evidence for anxiety and pain reduction in cancer populations. Mindfulness-based stress reduction (MBSR) has been shown to reduce psychological distress, improve sleep quality, and enhance coping in GI cancer patients. Adaptable to bedside and caregiver populations.
Mistletoe / Iscador
Grade CIscador SQ injection per protocol; varies by preparation
Some QoL data in GI cancers, primarily from European studies. Grade C evidence. May improve fatigue and overall well-being. Important: discuss potential interaction with antiangiogenic therapy (bevacizumab history). Not FDA-approved in the US but patients may source independently.
Omega-3 for Cachexia
Grade CEPA 2–3 g/day oral; high EPA:DHA ratio preferred
Limited but promising signal for muscle mass preservation in cancer cachexia. EPA supplementation may modulate inflammatory mediators driving cachexia in CRC. Not advised in patients with active GI bleeding or coagulopathy. Capsules problematic with dysphagia — use liquid formulations.[18]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to CRC. Patients will use supplements — this section helps you have the right conversation.
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade A | 1 g/day in divided doses | Nausea (CINV and cancer-related). Strong evidence. Safe. | Mild antiplatelet effect. Caution with active GI bleeding. Avoid oral route in complete obstruction. |
| Peppermint Oil | Grade B | Enteric-coated capsules, 0.2 mL TID | IBS-type cramping, abdominal spasm. Useful for non-obstructive GI discomfort. | Avoid with antacids (enteric coating dissolves early). May worsen GERD. Not for complete obstruction. |
| Aloe Vera Juice | Grade C | 30–60 mL daily oral | Mild constipation relief. Mucosal soothing. | Caution with electrolyte imbalance (can cause hypokalemia). Avoid in complete obstruction. Latex component is a stimulant laxative. |
| Turmeric / Curcumin | Grade C | 2–4 g/day with piperine | Anti-inflammatory. Phase IIa CRC data (safe with FOLFOX). 40% ACF reduction in one trial.[19] | CYP3A4 interaction with some targeted agents. Antiplatelet caution in bleeding patients. Avoid in biliary obstruction and active GI hemorrhage. |
| Glutamine | Grade C | 10–30 g/day oral in divided doses | Mucosal protection during chemotherapy. May reduce mucositis and diarrhea. | Limited hospice-specific evidence. Avoid in hepatic encephalopathy (ammonia precursor). Monitor in renal impairment. |
🚫 Avoid in This Diagnosis
- Cascara / Senna in complete obstruction: Stimulant laxatives are contraindicated in complete bowel obstruction — they will worsen obstruction, increase cramping, and risk perforation. This is the most common dangerous error in CRC hospice care.
- High-dose fish oil in GI bleeding patients: Antiplatelet effect at doses >3 g/day. Risk of worsening tumor hemorrhage in patients with active rectal or colonic bleeding.
- Black cohosh: Hepatotoxicity risk in liver-metastasis patients. CRC frequently metastasizes to liver — avoid in patients with known hepatic disease or elevated LFTs.
- Laxative herbs (senna, cascara, rhubarb root): All stimulant laxatives if obstruction is suspected or confirmed. Even partial obstruction is a contraindication for aggressive bowel stimulation.
Timeline Guide
A guide, not a prediction. CRC has one of the most variable trajectories in oncology — a patient with resectable liver-only mets may live years; one with peritoneal carcinomatosis and MBO may have weeks.
Your job is to figure out which clock your patient is on. Is food going in and staying in? Is the stoma still producing? Is the ascites new? Those are your clocks. Stage IV CRC with modern therapy (FOLFOXIRI + bevacizumab) has median OS of 25–31 months. MSI-H with immunotherapy: durable responses beyond 3 years. Peritoneal carcinomatosis: 6–12 months from diagnosis of peritoneal mets. MBO: weeks.[12]
YRS–
MOS
MOS
Stage I–III Post-Resection / Surveillance Phase
- Curative surgery ± adjuvant chemotherapy complete. 5-year survival 60–91% depending on stage.
- Surveillance phase: CEA monitoring every 3–6 months, CT imaging, colonoscopy per guidelines.
- Palliative care integration should begin at any recurrence, even if not yet hospice-appropriate.
- Focus: advance care planning, goals-of-care conversations, establish hospice team relationship early.
MOS–
1 YR
1 YR
Metastatic CRC on First/Second-Line Therapy
- Liver metastases developing or progressing. Intermittent GI symptoms — cramping, altered bowel habits, early satiety.
- Second-line therapy phase: response rates declining, cumulative toxicity rising (neuropathy, fatigue, myelosuppression).
- CEA trending upward despite treatment signals progression.
- Focus: symptom management escalation, palliative care deepens, hospice transition conversation begins.
WKS–
MOS
MOS
Progression Through Multiple Lines / Hospice Transition
- Progression through ≥2 lines of chemotherapy. Peritoneal disease developing or worsening. Obstruction risk rising.
- ECOG 3–4. Weight loss >10%. Oral intake diminishing. Ascites may appear.
- Obstruction episodes — partial initially, progressing to complete. Ostomy output character changing.
- Focus: hospice enrollment, comfort kit preparation, caregiver education, goals-of-care finalization. Have the bowel obstruction plan in place now.
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Obstruction or near-obstruction present. Inability to maintain oral intake. Vomiting may be intractable without octreotide.
- Ascites requiring frequent paracentesis (taps becoming less effective, shorter-lasting).
- Opioid requirements increasing rapidly. Pain from pelvic invasion or peritoneal disease escalating.
- Convert oral medications to SQ route. Ensure octreotide and haloperidol are available at bedside before the crisis.
HRS–
DAYS
DAYS
Final Hours
- Complete obstruction may be present. Discontinue all oral medications. Convert everything to SQ route.
- Cheyne-Stokes or agonal breathing; mottling of knees and feet; mandibular breathing.
- Family education: what the bowel sounds mean (gurgling, silence), why vomiting may continue (venting G-tube drainage protocol if in place), why abdomen is distended.
- Prepare for potential rectal bleeding event in final hours — dark towels, calm plan, midazolam drawn and ready if catastrophic bleed occurs.
Medications to Anticipate
Symptom-targeted pharmacology for CRC. What to have in the comfort kit, what to titrate first, and what the evidence supports.
The dominant symptom driving medication decisions in CRC hospice care is malignant bowel obstruction — and the triad of octreotide + haloperidol + dexamethasone is your workhorse. Pain management follows, with opioids transitioned to SQ as obstruction advances. The comfort kit must be built for the bowel obstruction crisis, not the generic cancer kit.[20]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine or Oxycodone | Opioid / Pain | Morphine 2.5–5 mg PO/SQ q4h; Oxy 5–10 mg PO q4h | First-line opioid. SQ preferred as obstruction advances. Titrate to effect. Add scheduled bowel regimen unless obstructed.[20] |
| Haloperidol | Antiemetic / Nausea from MBO | 0.5–2 mg SQ q6h or CSCI | Superior to metoclopramide in bowel obstruction (metoclopramide is contraindicated in complete obstruction). D2 antagonist. Antiemetic of choice via SQ in MBO.[5] |
| Octreotide | Somatostatin analog / MBO secretions | 300–600 mcg/24h SQ CSCI | Reduces GI secretions, decreases vomiting volume, transforms MBO management. First-line for MBO symptom control. Underused in hospice. Must be available before vomiting crisis.[5] |
| Dexamethasone | Corticosteroid / MBO edema, appetite, pain adjunct | 4–8 mg IV/SQ daily | May resolve partial obstruction from inflammatory edema. Appetite stimulant. Pain adjunct. Short-term benefit; monitor for delirium, hyperglycemia. |
| Hyoscine butylbromide or Glycopyrrolate | Anticholinergic / Secretions, cramping | Hyoscine 40–120 mg/24h CSCI; Glycopyrrolate 0.2 mg SQ q4h | Secretion reduction and cramping relief in MBO. Glycopyrrolate preferred in conscious patients (no CNS effects). Hyoscine does not cross BBB — less sedation. |
| Midazolam | Benzodiazepine / Terminal agitation, refractory symptoms | 2.5–5 mg SQ PRN; 10–40 mg/24h CSCI | Terminal agitation, catastrophic symptom management, palliative sedation basis. Have in comfort kit drawn and labeled. Prepare family. |
| Ondansetron | 5-HT3 antagonist / Nausea adjunct | 4–8 mg PO/SQ q8h | Nausea adjunct. Safer than metoclopramide when obstruction is uncertain. Constipating — use with awareness in CRC patients. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for CRC
Patients with peritoneal disease or known obstruction risk — octreotide and haloperidol must be available at the bedside before the vomiting crisis occurs. Do not wait for the first episode of intractable vomiting to order these. Crisis kit: Octreotide 600 mcg/24h CSCI supplies, Haloperidol 2 mg SQ x3 doses, Midazolam 5 mg SQ x3 (drawn and labeled for catastrophic bleed or refractory agitation), Glycopyrrolate 0.2 mg SQ x3. If venting gastrostomy is in place: drainage bag supplies and flushing protocol.
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Malignant bowel obstruction is not a surgical emergency in hospice
Medical management works and surgery at this stage has high perioperative mortality (20–40% at 40–90 days). Octreotide + haloperidol + dexamethasone ± venting gastrostomy. Stop all stimulant laxatives and prokinetics immediately. Communicate this to the ER before the patient arrives there.[5]
2
Octreotide is underused in hospice
It transforms MBO management. Reduces GI secretions, decreases vomiting volume, and at 300–600 mcg/24h SQ CSCI, gives patients meaningful symptom relief. Most hospice agencies don't stock it routinely — change that for your CRC patients. Order it at admission if peritoneal disease is present.
3
Ostomy assessment every visit — output changes signal obstruction first
Output character changes (watery to thick, thick to absent, color change, blood) signal obstruction before clinical symptoms appear. High-output ileostomy (>1500 mL/day): dehydration crisis in slow motion. Absent output for >4–6 hours in a previously productive stoma: assess for obstruction immediately. Peristomal skin, appliance seal integrity, herniation — check every time.[7]
4
Tenesmus in rectal cancer is one of the most undertreated symptoms in hospice
Constant rectal urgency and pressure from rectal tumor invasion. Opioids alone often fail — may paradoxically worsen. Responds to low-dose amitriptyline (10–25 mg QHS) and rectal dexamethasone suppositories. Consider hyoscine butylbromide for spasm component. Palliative short-course RT consultation if still appropriate — 71–90% symptomatic response.[21]
5
Fistula formation is a disease complication, not a wound care failure
Rectovaginal, colovesical, and enterocutaneous fistulas are disease complications of locally advanced CRC — especially in patients with bevacizumab history. Manage expectations early: warn families before it happens. Signs: stool in urine, stool from vagina, fecal drainage from surgical sites. This is not a failure of care. Pouching systems, wound VAC consultation, and odor management are the response.
"The ER wants to scan it. The surgeon wants to cut it. At stage IV CRC with peritoneal carcinomatosis, surgery gives you a 20–40% chance of dying perioperatively and the rest don't get better. Octreotide, dexamethasone, haloperidol, and a venting tube. That's the answer."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Body image, dignity, genetic guilt, and the unique psychosocial burden of dying from colorectal cancer. The symptom burden you can't see on a vitals sheet.
Colorectal cancer carries psychosocial burdens that are distinct from most other cancers. The disease attacks the most private bodily functions — bowel control, continence, sexuality, body image. These are not secondary concerns. For many CRC patients, the psychosocial suffering equals or exceeds the physical suffering.[22]
CRC-Specific Psychosocial Themes
Body Image & Dignity — Ostomy Patients
Ostomy patients experience profound body image disruption. The bag, the odor, the loss of control over when and how waste leaves the body — this is a dignity crisis. Normalize it. Connect to ostomy nurse. Address it directly with the patient and partner. Ask: "How has the ostomy affected how you feel about yourself?" Don't wait for them to bring it up.[23]
Bowel Function & Dignity
Loss of bowel control is one of the most feared aspects of dying for CRC patients. Incontinence, fecal leakage, odor, visible stool — patients stop socializing, stop allowing visitors, stop leaving bed. Address it clinically: containment products, skin care, odor management, room sprays. Address it with compassion: "This is the disease, not you. We have ways to manage this."
Younger Patients — Rising Incidence Under 50
CRC incidence is rising in people under 50. Younger patients have dependent children, active careers, unfinished life. Grief is different — it includes the loss of a future, not just the end of a past. These patients need targeted psychosocial support: legacy work with children, career/financial planning assistance, and grief support that acknowledges the specific injustice of dying young.[8]
Genetic Guilt — Lynch Syndrome Families
Lynch syndrome families carry enormous burden. The dying patient may feel guilt about passing on the gene. Surviving children face fear about their own risk. Genetic counseling referral is appropriate even at hospice enrollment — not for the patient, but for the family's future. Frame it as a gift: "Your diagnosis can protect your children through early screening."
Psychological Distress Screening
Depression — Screen Every Patient
Grade BSingle-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously
- Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
Anxiety & Existential Distress
Grade B- Distinguish anxiety subtypes: Situational, generalized, existential, death anxiety — each responds differently
- Lorazepam 0.5 mg PRN for acute anxiety episodes
- Dignity therapy: Structured life narrative intervention — reduces suffering and increases sense of meaning
- Refer to social work and chaplain at enrollment — not at crisis
Goals-of-Care Framing
Clinical Pearl — The Operative Goal
"Staying home without a tube in my stomach" is often the operative goal for CRC patients. Name it. When you ask "What matters most to you?" — many CRC patients will describe comfort in terms of what they don't want: no more hospital, no more surgery, no more bags. Listen for that framing and use it to anchor every clinical decision that follows.
Spiritual Assessment
Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?" This opens spiritual conversation without assuming any tradition. For CRC patients specifically, body image disruption and loss of bowel function may trigger spiritual crisis around dignity and self-worth. Chaplaincy involvement should begin at enrollment.
"The ostomy bag that's been leaking for three days isn't a nursing problem. It's a dignity emergency. Fix it first. Talk about goals of care second. Nobody listens to anything you say when they've been sitting in their own waste."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Colorectal cancer at this stage affects the entire body, but the bowel causes the most day-to-day challenges. You may see symptoms that are distressing to watch — nausea, vomiting, changes in the ostomy bag, abdominal swelling, and increasing pain. These are signs of the disease advancing, not things you caused or could have prevented. Your job is to be present, watch for changes, and call the hospice team when anything worries you.
Próximamente en español. — Coming soon in Spanish.
What You May See
- Nausea and vomiting: May be severe if the bowel is blocked. Medications can help significantly — call the nurse if vomiting won't stop.
- Abdominal distension: Belly may look swollen from fluid buildup (ascites) or trapped air from obstruction. This is expected.
- Ostomy output changes: Color, consistency, and volume may change. Teach yourself what normal looks like now. If output stops completely for more than 6 hours, call the nurse.
- Increasing pain: Especially crampy abdominal pain. Medications will be adjusted — don't let pain go unreported.
- Extreme fatigue and weakness: Sleeping most of the day is normal at this stage.
- Appetite loss: Your loved one will eat less and less. This is the disease, not starvation.
How You Can Help
- Small sips only if vomiting: Do not push fluids or food into an obstructed bowel. Small sips of clear favorites. Ice chips. Good mouth care.
- Ostomy bag management: Check daily. A good seal prevents leaks and skin irritation. If the bag hasn't produced for 4+ hours and your loved one is uncomfortable, call the nurse.
- Position for comfort: Semi-recumbent (head of bed elevated 30–45°) reduces nausea and breathing difficulty from abdominal distension.
- Don't force eating: Cachexia is not starvation. The body cannot use food the way it used to. Forcing eating causes more suffering, not strength.
- Be present: You don't have to fix anything. Silence and touch are profoundly therapeutic. Sitting with someone who is suffering is one of the bravest things a human being can do.
📞 Call the nurse immediately if you see:
Sudden severe abdominal pain that is new or much worse than usual. Vomiting that won't stop despite medications. Ostomy output completely stops for more than 6 hours. A large amount of bright red blood (more than 2–3 tablespoons) from the rectum or ostomy. Signs of perforation: rigid, board-like abdomen that is extremely tender to touch. Inability to be woken or sudden change in consciousness.
🙏 Families of colorectal cancer patients often feel helpless because the GI symptoms are visible and distressing — the smell, the bags, the bodily fluids, the equipment. Reframe your role: you are not here to fix this. You are here to witness it, to be present through it, and to make sure your loved one knows they are not alone. Research shows that patients who have people present in their final days experience less distress — not just emotionally, but clinically. You are part of the treatment team whether you know it or not.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Octreotide in obstruction — order it at admission. Don't wait for the first vomiting crisis to scramble for this drug. If your CRC patient has peritoneal disease, carcinomatosis on imaging, or any history of partial obstruction, octreotide 300–600 mcg/24h CSCI should be in your comfort kit from day one. It transforms obstruction management. The difference between a patient vomiting every 30 minutes and a patient resting comfortably is often this one drug.
- 02The surgical conversation — have it before the ER does. At stage IV CRC with peritoneal carcinomatosis, surgery for bowel obstruction carries 20–40% perioperative mortality and the rest don't get better. Medical management is the right answer. Tell the patient. Tell the family. Document it. Put it in the plan of care. Because when that obstruction happens at 2 AM and the family panics and calls 911, the ER surgeon will want to operate. Your advance conversation is the only thing standing between your patient and a death in the ICU.
- 03Assess the ostomy like it's a vital sign. Output character, volume, and skin integrity tell you more about disease trajectory than most lab values. A high-output ileostomy in a patient who can't keep up with PO hydration is a dehydration crisis in slow motion. Color change from normal to dark or bloody signals tumor progression or bleeding. No output for hours in a previously productive stoma — that's obstruction until proven otherwise. Act before the labs show it.
- 04Tenesmus is undertreated because most clinicians don't assess for it. That constant rectal pressure and urgency from tumor invasion — patients are embarrassed to bring it up. Ask directly: "Do you have a constant feeling of needing to have a bowel movement?" Opioids alone don't work well for this. Low-dose amitriptyline 10–25 mg at bedtime, rectal dexamethasone suppositories, and hyoscine butylbromide for spasm. Consider palliative RT — 71–90% symptomatic response rate for rectal symptoms.
- 05Opioid rotation in renal compromise — CRC patients with liver mets. CRC commonly metastasizes to the liver, which affects drug metabolism. As liver function declines, morphine metabolites accumulate (M3G, M6G) — increasing toxicity risk. If your patient on morphine develops myoclonus, confusion, or escalating sedation without escalating pain, think opioid rotation. Hydromorphone has a cleaner metabolic profile. Fentanyl patch is an option in stable patients but avoid in cachexia — erratic absorption through wasted subcutaneous tissue.
- 06Lynch syndrome family counseling — even at enrollment. If MSI-H or Lynch syndrome is confirmed in the chart, first-degree relatives face a 40–80% lifetime CRC risk. This is not a conversation to defer because the patient is dying. It's a conversation to have precisely because the patient is dying — and their diagnosis can save their children's lives through enhanced screening. Provide genetic counseling contact information. Document the conversation.
- 07The feeding conversation — have it before the family forces food. "He's not eating" is the most common family complaint in CRC hospice. Cachexia is not starvation. The cancer has hijacked the body's metabolic machinery. Forcing food into an obstructed or near-obstructed bowel causes vomiting, aspiration, and suffering. Have the conversation early: "Small sips of favorite things. Good mouth care. Your love is more nourishing than any meal right now."
- 08Body image in ostomy patients is a clinical problem, not a soft skills problem. CRC patients with ostomies experience profound body image disruption that affects mood, intimacy, social engagement, and willingness to accept visitors. Ask about it directly. Connect to ostomy nurse if available. For partnered patients, address intimacy concerns proactively — most couples are too embarrassed to bring it up. Dignity preservation is clinical care.
- 09Prepare for fistulas before they happen. Rectovaginal and colovesical fistulas are disease complications of locally advanced CRC — especially with bevacizumab history. If your patient's records show tumor invasion near the bladder or vaginal cuff, or prior bevacizumab, warn the family before the fistula forms: "The cancer may create a connection between the bowel and another organ. If you notice stool in urine or stool coming from unexpected places, call us. We have ways to manage this. It is not a failure of care."
- 10Caregiver burnout in CRC is among the highest of any cancer type. GI symptoms are exhausting to witness and manage — the smell, the bags, the bodily fluids, the equipment, the constant vigilance for obstruction signs. Caregiver economic burden data shows CRC caregiving is among the most costly in time and money. Screen for caregiver burnout at every visit. Ask directly: "How are you doing — not your loved one, you." Connect to social work, respite care, and caregiver support groups. The caregiver who burns out puts your patient in the ER.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
2
National Cancer Institute. SEER Cancer Stat Facts: Colorectal Cancer. Surveillance, Epidemiology, and End Results Program. 2024.
3
Stewart CL et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018;55(9):330-379.
4
Taieb J et al. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. Eur J Cancer. 2022;175:136-157.
5
Banting SP et al. Management of primary and metastatic malignant small bowel obstruction, operate or palliate. A systematic review. ANZ J Surg. 2020;91(3):282-290.
6
Gorin SS. Care of Cancer Survivors: Special Issues for Colorectal Cancer Survivors. FP Essent. 2023;529:23-33.
7
Ambe PC et al. Intestinal Ostomy. Dtsch Arztebl Int. 2018;115(11):182-187.
8
Ranson S et al. Difficulties and Disparities in Colorectal Cancer End-of-Life Care: A Patient's Story. Clin Colon Rectal Surg. 2024;38(1):74-80.
9
Keating NL et al. Outpatient palliative care and end-of-life care intensity: linking Massachusetts Cancer Registry with All-Payer Claims Database. JNCI Cancer Spectr. 2025;9(1).
10
Kaplan J et al. Enteral stents for the management of malignant colorectal obstruction. World J Gastroenterol. 2014;20(37):13239-45.
11
Dalal KM et al. Management of patients with malignant bowel obstruction and stage IV colorectal cancer. J Palliat Med. 2011;14(7):822-8.
12
Loupakis F et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer (TRIBE Trial). N Engl J Med. 2014;371(17):1609-18.
13
Lee SW et al. Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer. Am J Hosp Palliat Care. 2017;35(1):166-172.
14
Massa I et al. Chemotherapy and palliative care near end-of-life in colorectal cancer patients. BMC Palliat Care. 2018;17(1):86.
15
Engstrand J et al. Colorectal cancer liver metastases — a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78.
16
Mack JW et al. Patient beliefs that chemotherapy may be curative and care received at the end of life in metastatic lung and colorectal cancer. Cancer. 2015;121(11):1891-7.
17
Uranga JA et al. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018;157:134-147.
18
Hu C et al. A Novel Definition and Grading Diagnostic Criteria for Tumour-Type-Specific Comprehensive Cachexia Risk. J Cachexia Sarcopenia Muscle. 2025;16(2):e13744.
19
Carroll RE et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011;4(3):354-64.
20
Pisano M et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018;13:36.
21
Cameron MG et al. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer — a systematic review. Acta Oncol. 2013;53(2):164-73.
22
Kristensen HØ et al. Surviving rectal cancer at the cost of a colostomy: global survey of long-term health-related quality of life in 10 countries. BJS Open. 2022;6(6).
23
Liu H et al. The Quality of Life of Patients with Colorectal Cancer and a Stoma in China. Adv Skin Wound Care. 2021;34(6):302-307.
24
Van Houtven CH et al. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist. 2010;15(8):883-93.
25
Howells LM et al. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer — Phase IIa RCT. J Nutr. 2019;149(7):1133-1139.
26
Winters KD et al. Palliation of Intractable Cancer-Related Pain With Low-Dose Epidural Bupivacaine. J Palliat Med. 2023;27(3):434-437.
27
Wu CC et al. Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care. Oncologist. 2016;21(6):771-7.
28
Ferreira F, Pedro A. Ganglion Impar Neurolysis in the Management of Pelvic and Perineal Cancer-Related Pain. Case Rep Oncol. 2020;13(1):29-34.
29
Dueland S et al. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases (SECA-II). Ann Surg. 2020;271(2):212-218.
30
Picardi V et al. Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2016;95(4):1184-90.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.